comparemela.com

Latest Breaking News On - Jiuyuan - Page 2 : comparemela.com

Novo Nordisk s Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk (NYSE:NVO)

Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024. Biosimilar Jiyoutai awaits approval in China. FDA tightens Mounjaro supply due to high demand.

China s first biosimilar Ozempic drug applies for approval

A Chinese drugmaker has developed a biosimilar version of Novo Nordisk s popular diabetes drug Ozempic and applied for its approval. Hangzhou Jiuyuan Gene Engineering said in a post.

Health: China s first biosimilar Ozempic drug applies for approval

Health: China s first biosimilar Ozempic drug applies for approval
gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.

Inner Mongolia added 135 local confirmed cases and 938 local asymptomatic infections

According to the website of the Inner Mongolia Health and Health Commission, from 0 to 24:00 on November 8, the Inner Mongolia Autonomous Region reported 135 new local confirmed cases, including 129 in Hohhot, 4 in Chifeng (all in Hongshan District), and 2 in Ordos ( 1 case in Dongsheng District and 1 case in Dalat Banner).

Inner Mongolia added 35 local confirmed cases and 79 asymptomatic infections

According to the official WeChat news of the Inner Mongolia Health and Health Commission, from 0 to 24:00 on October 25, the Inner Mongolia Autonomous Region reported no new imported confirmed cases and asymptomatic infections. 4 imported confirmed cases were cured and discharged, and 1 imported asymptomatic infection was released from medical observation, all of which were diverted from the capital airport international flight to Hohhot Baita International Airport.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.